65 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
Pfizer RSV vaccine maintains protection in older adults over two seasons in trial https://www.cnbc.com/2024/02/29/pfizer-rsv-vaccine-protects-older-adults-over-two-seasons.html Feb 29, 2024 - The results come ahead of a meeting of an advisory panel to the CDC, which will consider whether seniors should take RSV shots annually or every other year.
Guggenheim upgrades GSK to buy from neutral https://seekingalpha.com/news/4075698-guggenheim-upgrades-gsk-to-buy-from-neutral?source=feed_sector_healthcare Mar 04, 2024 - Guggenheim upgrades GSK (GSK) stock to buy, citing higher revenue estimates, improving margins, and potential resolution of the Zantac overhang. Read more here.
Sen. Warren accuses GSK of price gouging over pediatric asthma drug https://seekingalpha.com/news/4075584-sen-warren-accuses-gsk-of-price-gouging-over-pediatric-asthma-drug?source=feed_sector_healthcare Mar 04, 2024 - U.S. Sen. Elizabeth Warren has slammed GSK (GSK) for alleged price-gouging over the marketing of its pediatric asthma drug Flovent HFA and its authorized generic. Read more here.
GSK's Jemperli Gets EU Nod for Endometrial Cancer Expanded Use https://www.zacks.com/stock/news/2196699/gsk-s-jemperli-gets-eu-nod-for-endometrial-cancer-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196699 Dec 12, 2023 - GSK's Jemperli combo receives the European Commission's marketing authorization as a frontline treatment for certain types of primary advanced/recurrent endometrial cancer.
GSK (GSK) Stock Moves -0.85%: What You Should Know https://www.zacks.com/stock/news/2200785/gsk-gsk-stock-moves-0-85-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2200785 Dec 20, 2023 - The latest trading day saw GSK (GSK) settling at $36.19, representing a -0.85% change from its previous close.
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA https://www.zacks.com/stock/news/2201156/merck-s-mrk-chronic-cough-drug-gets-another-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201156 Dec 21, 2023 - Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate https://www.zacks.com/stock/news/2201105/gsk-hansoh-ink-deal-to-develop-lung-cancer-adc-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201105 Dec 21, 2023 - GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.
GSK (GSK) Rises As Market Takes a Dip: Key Facts https://www.zacks.com/stock/news/2204687/gsk-gsk-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2204687 Jan 02, 2024 - GSK (GSK) concluded the recent trading session at $37.51, signifying a +1.21% move from its prior day's close.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar https://www.zacks.com/stock/news/2206174/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2206174 Jan 05, 2024 - The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Glaxo (GSK) is Poised to Beat Earnings Estimates Again https://www.zacks.com/stock/news/2206453/why-glaxo-gsk-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2206453 Jan 05, 2024 - Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pages: 1234567

<Page 2>